PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET. This event will include one-on-one investor meetings, emphasizing PMV's focus on tumor-agnostic therapies targeting p53 mutants. The company is recognized for its groundbreaking work in p53 biology, established by co-founder Dr. Arnold Levine in 1979. For more details, visit PMV Pharma's website.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -3.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharmaceuticals in a “Fireside Chat” at the Guggenheim Healthcare Talks 2022 Oncology Day taking place on February 9, 2022. The company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
Guggenheim Healthcare Talks 2022 Oncology Day
| Date: | Wednesday, February 9, 2022 |
| Time: | 10:30 am ET |
| Format: | Fireside Chat |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
For Investors:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.